期刊
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 15, 期 4, 页码 -出版社
SPRINGER
DOI: 10.1007/s11910-015-0531-7
关键词
Neuroinflammation; Dementia; Alzheimer; Parkinson; Lewy body; Frontotemporal
资金
- University of Pisa
- PAIM (Pisa, Italy)
- Acadia Pharmaceuticals Inc
- Amsterdam Molecular Therapeuctics BV
- AstraZeneca
- BiogeIdec
- NeuroNova AB
- Eli Lilly and Company
- Medtronic Inc
- Shire Pharmaceuticals Inc
- Synosia Therapeutics AG
- GlaxoSmith Kline
- UBC Biosciences Inc
- Veralis (RD) limited
- Genentech Inc
- Navidea
- Medical Research Council, UK
- Alzheimer's Research, UK
- Alzheimer's Society, UK
- Novo Nordisk
- GE Healthcare
- Piramal Life Science
- MRC [G84/6523] Funding Source: UKRI
- Medical Research Council [G84/6523] Funding Source: researchfish
The molecular mechanism of neuronal loss and synaptic damage in Alzheimer's disease (AD), Parkinson's disease dementia (PDD), frontotemporal dementia (FTD) and Lewy body dementia (LBD) is poorly understood and could differ among different types of neurodegenerative processes. However, the presence of neuroinflammation is a common feature of dementia. In this setting, reactive microgliosis, oxidative damage and mitochondrial dysfunction are associated with the pathogenesis of all types of neurodegenerative dementia. Moreover, an increased body of evidence suggests that microglia may play a central role in AD progression. In this paper, we review the scientific literature on neuroinflammation related to the most common neurodegenerative dementias (AD, PDD, FTD and LBD) focussing on the possible molecular mechanisms and the available clinical evidence. Furthermore, we discuss the neuroimaging techniques that are currently used for the study of neuroinflammation in human brain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据